Abstract:Antiangiogenesis therapy has become a hot field in cancer research. Blood vessels of tumor carry specific markers that are usually related to angiogenesis. Study of these heterogeneous molecules in different tumor vessels may be beneficial for promoting antiangiogenic therapy. In this study, we established an in vitro co-culture model of human umbilical vein endothelial cells (HUVECs) and gastric adenocarcinoma cell line SGC7901, screened the peptides binding specifically to the HUVECs co-cultured with gastric cancer cells (Co-HUVECs) using phage display peptides library, and studied the affinity of these peptides to gastric cancer vascular endothelial cells. After four rounds of panning, there was an obvious enrichment for the phages specifically binding to the Co-HUVECs, and the output/input ratio of Co-HUVECs increased about 590-fold (from 0.95×10−7 to 561.25×10−7). Five phage clones (M6, M3, M9, IN12, IN11), which could strongly bind to Co-HUVECs instead of wild-type HUVECs, were characterized by ELISA. In vitro cellular binding assay showed that phage IN11 preferably bound to Co-HUVECs rather than control HUVECs, and the number of the phage IN11 recovered from Co-HUVECs was 5.7- and 16.9-folds, respectively, as much as those from control HUVECs and GES cells. Immunocytochemical and immunohistochemical staining confirmed that phage IN11 could specifically bind to Co-HUVECs as well as vascular endothelial cells in gastric cancer tissue sections. Competitive and inhibitory assay revealed the synthetic peptide GEBP11 (CTKNSYLMC) displayed on phage IN11 could competitively inhibit binding of the phage IN11 to Co-HUVECs. Immunofluorescence microscopy showed that the fluorescence-labeled peptide GEBP11 was located at the membrane and perinuclear cytoplasm of Co-HUVECs. Meanwhile, GEBP11 was found to be able to target the gastric cancer vascular endothelial cells. Therefore, GEBP11 may be a potential candidate for targeted drug delivery in antivascular therapy and diagnosis of gastric cancer.

[Screening for inhibitor of vascular endothelial growth factor from random peptide library].

Screening and Characterization of Inhibiting Peptides Binding to the Tumor Vascular Growth Factor Receptor

The Improvement in Screening for Vascular Endothe Lial Growth Factor Receptor Flt-1 Antagonists in a Phage Display Library

A Peptide Fusion Protein Inhibits Angiogenesis and Tumor Grow- Th by Blocking VEGF Binding to KDR

A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor.

Discovering Small Molecule Ligands of Vascular Endothelial Growth Factor That Block Vegf-Kdr Binding Using Label-Free Microarray-Based Assays

Discovery of VEGF-KDR Binding Inhibitors by Screening Small-Molecule Microarrays with Label-Free Ellipsometric Scanners

[Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1]

Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening.

Identification Of Vegfr2-Binding Peptides Using High Throughput Bacterial Display Methods And Functional Assessment

Research on Inhibition Activity of a Single Chain Fv (scFv) against Vascular Endothelial Growth Factor Receptor 2

Screening of Phages Specifically Combined with Connective Tissue Growth Factor from a Random 12-Peptide Library

[Development of toxin targeting to VEGF-KDR].

Expression and purification of human vascular-endothelial-growth-factor-receptor-2 tyrosine kinase in Streptomyces for inhibitor screening.

Phage‐derived Fully Human Antibody Scfv Fragment Directed Against Human Vascular Endothelial Growth Factor Receptor 2 Blocked Its Interaction with VEGF

Screening and Identification of Vascular-Endothelial-cell-specific Binding Peptide in Gastric Cancer

Cloning of cDNA Encoding Extra-Cellular Domain of Human VEGF Receptor KDR and Effect of Its Recombinant Protein on Endothelial Cell Proliferation and Angiogenesis

[Selection and Characterization of Human Antibodies Against Vascular Endothelial Growth Factor from Human Phage Display Antibody Library].

[Screening Human Keratinocyte Growth Factor Mimic Peptide with Ph.D.-7 Phage Display Peptide Library].

A Novel Peptide Specifically Binding to VEGF Receptor Suppresses Angiogenesis in Vitro and in Vivo

Prokaryotic Expression of VEGF165 and Preliminary Screening of Anti-VEGF Hybridoma Cell Lines